AR090259A1 - Inhibidores de benzodioxano de la produccion de leucotrieno para terapia de combinacion - Google Patents
Inhibidores de benzodioxano de la produccion de leucotrieno para terapia de combinacionInfo
- Publication number
- AR090259A1 AR090259A1 ARP130100729A ARP130100729A AR090259A1 AR 090259 A1 AR090259 A1 AR 090259A1 AR P130100729 A ARP130100729 A AR P130100729A AR P130100729 A ARP130100729 A AR P130100729A AR 090259 A1 AR090259 A1 AR 090259A1
- Authority
- AR
- Argentina
- Prior art keywords
- dihydro
- benzodioxin
- benzyl
- alkyl
- members
- Prior art date
Links
- BNBQRQQYDMDJAH-UHFFFAOYSA-N benzodioxan Chemical compound C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 25
- -1 -OH Chemical group 0.000 abstract 18
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 8
- 125000005843 halogen group Chemical group 0.000 abstract 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 6
- 150000003254 radicals Chemical class 0.000 abstract 6
- 125000001072 heteroaryl group Chemical group 0.000 abstract 5
- 125000002619 bicyclic group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- KKZHBMBXVUWCEB-FUHIMQAGSA-N (1r,3s)-3-[[4-[(3s)-2,3-dihydro-1,4-benzodioxin-3-yl]phenyl]methylamino]cyclopentane-1-carboxylic acid Chemical compound C1[C@H](C(=O)O)CC[C@@H]1NCC1=CC=C([C@@H]2OC3=CC=CC=C3OC2)C=C1 KKZHBMBXVUWCEB-FUHIMQAGSA-N 0.000 abstract 1
- KRFKFVQYTOGGAO-MJTSIZKDSA-N (2r)-n-[[4-(2,3-dihydro-1,4-benzodioxin-3-yl)phenyl]methyl]butan-2-amine Chemical compound C1=CC(CN[C@H](C)CC)=CC=C1C1OC2=CC=CC=C2OC1 KRFKFVQYTOGGAO-MJTSIZKDSA-N 0.000 abstract 1
- UDJZYDQHVANVDQ-UCFFOFKASA-N (3s)-1-[[4-(2,3-dihydro-1,4-benzodioxin-3-yl)phenyl]methyl]pyrrolidin-3-ol Chemical compound C1[C@@H](O)CCN1CC1=CC=C(C2OC3=CC=CC=C3OC2)C=C1 UDJZYDQHVANVDQ-UCFFOFKASA-N 0.000 abstract 1
- GIHISTJSSTWMSK-VQCQRNETSA-N 1-[1-[[4-[(3s)-2,3-dihydro-1,4-benzodioxin-3-yl]phenyl]methyl]piperidin-4-yl]-2,2,2-trifluoroethanol Chemical compound C1CC(C(O)C(F)(F)F)CCN1CC1=CC=C([C@@H]2OC3=CC=CC=C3OC2)C=C1 GIHISTJSSTWMSK-VQCQRNETSA-N 0.000 abstract 1
- BXQNWPDFFXOOSE-UHFFFAOYSA-N 1-[4-(2,3-dihydro-1,4-benzodioxin-3-yl)phenyl]-n-(pyridin-3-ylmethyl)methanamine Chemical compound C=1C=C(C2OC3=CC=CC=C3OC2)C=CC=1CNCC1=CC=CN=C1 BXQNWPDFFXOOSE-UHFFFAOYSA-N 0.000 abstract 1
- QXJMPASXBVNSFF-UHFFFAOYSA-N 1-[4-(2,3-dihydro-1,4-benzodioxin-3-yl)phenyl]-n-[(1-methylimidazol-4-yl)methyl]methanamine Chemical compound CN1C=NC(CNCC=2C=CC(=CC=2)C2OC3=CC=CC=C3OC2)=C1 QXJMPASXBVNSFF-UHFFFAOYSA-N 0.000 abstract 1
- CVTDCBZGXNQNOC-UHFFFAOYSA-N 1-[4-[[4-(2,3-dihydro-1,4-benzodioxin-3-yl)phenyl]methyl]-1,4-diazepan-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCCN1CC1=CC=C(C2OC3=CC=CC=C3OC2)C=C1 CVTDCBZGXNQNOC-UHFFFAOYSA-N 0.000 abstract 1
- CAGXWFYGUAYMSE-UHFFFAOYSA-N 1-[4-[[4-(2,3-dihydro-1,4-benzodioxin-3-yl)phenyl]methyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1CC1=CC=C(C2OC3=CC=CC=C3OC2)C=C1 CAGXWFYGUAYMSE-UHFFFAOYSA-N 0.000 abstract 1
- CSSWHSHPOXYSIX-HSZRJFAPSA-N 1-[4-[[4-[(3s)-2,3-dihydro-1,4-benzodioxin-3-yl]phenyl]methyl-methylamino]piperidin-1-yl]ethanone Chemical compound C=1C=C([C@@H]2OC3=CC=CC=C3OC2)C=CC=1CN(C)C1CCN(C(C)=O)CC1 CSSWHSHPOXYSIX-HSZRJFAPSA-N 0.000 abstract 1
- IMUNDANBVWUJDD-UHFFFAOYSA-N 1-[[1-[[4-(2,3-dihydro-1,4-benzodioxin-3-yl)phenyl]methyl]piperidin-3-yl]methyl]pyrrolidin-2-one Chemical compound O=C1CCCN1CC1CN(CC=2C=CC(=CC=2)C2OC3=CC=CC=C3OC2)CCC1 IMUNDANBVWUJDD-UHFFFAOYSA-N 0.000 abstract 1
- GGZCIVBVROGRON-UHFFFAOYSA-N 1-[[1-[[4-(2,3-dihydro-1,4-benzodioxin-3-yl)phenyl]methyl]piperidin-4-yl]methyl]pyrrolidin-2-one Chemical compound O=C1CCCN1CC1CCN(CC=2C=CC(=CC=2)C2OC3=CC=CC=C3OC2)CC1 GGZCIVBVROGRON-UHFFFAOYSA-N 0.000 abstract 1
- BMAGRRHGNCMAKG-UHFFFAOYSA-N 1-[[4-(2,3-dihydro-1,4-benzodioxin-3-yl)phenyl]methyl]-3-methoxyazetidine Chemical compound C1C(OC)CN1CC1=CC=C(C2OC3=CC=CC=C3OC2)C=C1 BMAGRRHGNCMAKG-UHFFFAOYSA-N 0.000 abstract 1
- BJNJPZKYXUDIPT-UHFFFAOYSA-N 1-[[4-(2,3-dihydro-1,4-benzodioxin-3-yl)phenyl]methyl]-4-fluoropiperidine Chemical compound C1CC(F)CCN1CC1=CC=C(C2OC3=CC=CC=C3OC2)C=C1 BJNJPZKYXUDIPT-UHFFFAOYSA-N 0.000 abstract 1
- GIAPCXVSIVXPAC-UHFFFAOYSA-N 1-[[4-(2,3-dihydro-1,4-benzodioxin-3-yl)phenyl]methyl]-4-methyl-1,4-diazepane Chemical compound C1CN(C)CCCN1CC1=CC=C(C2OC3=CC=CC=C3OC2)C=C1 GIAPCXVSIVXPAC-UHFFFAOYSA-N 0.000 abstract 1
- JZOWDWQNFWPYOL-UHFFFAOYSA-N 1-[[4-(2,3-dihydro-1,4-benzodioxin-3-yl)phenyl]methyl]-4-methylsulfonylpiperidine Chemical compound C1CC(S(=O)(=O)C)CCN1CC1=CC=C(C2OC3=CC=CC=C3OC2)C=C1 JZOWDWQNFWPYOL-UHFFFAOYSA-N 0.000 abstract 1
- AHAYWUVNWOWZOT-UHFFFAOYSA-N 1-[[4-(2,3-dihydro-1,4-benzodioxin-3-yl)phenyl]methyl]-4-phenylpiperidin-4-ol Chemical compound C1CN(CC=2C=CC(=CC=2)C2OC3=CC=CC=C3OC2)CCC1(O)C1=CC=CC=C1 AHAYWUVNWOWZOT-UHFFFAOYSA-N 0.000 abstract 1
- PCFCFIXIKAEWEU-UHFFFAOYSA-N 1-[[4-(2,3-dihydro-1,4-benzodioxin-3-yl)phenyl]methyl]-n,n-dimethylpiperidine-4-carboxamide Chemical compound C1CC(C(=O)N(C)C)CCN1CC1=CC=C(C2OC3=CC=CC=C3OC2)C=C1 PCFCFIXIKAEWEU-UHFFFAOYSA-N 0.000 abstract 1
- IRISHRRTQYSYKF-UHFFFAOYSA-N 1-[[4-(2,3-dihydro-1,4-benzodioxin-3-yl)phenyl]methyl]-n-methylpiperidine-4-carboxamide Chemical compound C1CC(C(=O)NC)CCN1CC1=CC=C(C2OC3=CC=CC=C3OC2)C=C1 IRISHRRTQYSYKF-UHFFFAOYSA-N 0.000 abstract 1
- XFUBEZLOZAPYEL-UHFFFAOYSA-N 1-[[4-(2,3-dihydro-1,4-benzodioxin-3-yl)phenyl]methyl]azetidine-3-carbonitrile Chemical compound C1C(C#N)CN1CC1=CC=C(C2OC3=CC=CC=C3OC2)C=C1 XFUBEZLOZAPYEL-UHFFFAOYSA-N 0.000 abstract 1
- ZKOQSOBMSMTLJU-UHFFFAOYSA-N 1-[[4-(2,3-dihydro-1,4-benzodioxin-3-yl)phenyl]methyl]pyrrolidine Chemical compound C=1C=C(C2OC3=CC=CC=C3OC2)C=CC=1CN1CCCC1 ZKOQSOBMSMTLJU-UHFFFAOYSA-N 0.000 abstract 1
- PCFCFIXIKAEWEU-JOCHJYFZSA-N 1-[[4-[(3s)-2,3-dihydro-1,4-benzodioxin-3-yl]phenyl]methyl]-n,n-dimethylpiperidine-4-carboxamide Chemical compound C1CC(C(=O)N(C)C)CCN1CC1=CC=C([C@@H]2OC3=CC=CC=C3OC2)C=C1 PCFCFIXIKAEWEU-JOCHJYFZSA-N 0.000 abstract 1
- WMAVIYXMZVDJHG-UHFFFAOYSA-N 1-cyclopropyl-n-[[4-(2,3-dihydro-1,4-benzodioxin-3-yl)phenyl]methyl]methanamine Chemical compound C=1C=C(C2OC3=CC=CC=C3OC2)C=CC=1CNCC1CC1 WMAVIYXMZVDJHG-UHFFFAOYSA-N 0.000 abstract 1
- ISPUBVOAHNAPRV-HXUWFJFHSA-N 2-[1-[[4-[(3s)-2,3-dihydro-1,4-benzodioxin-3-yl]phenyl]methyl]piperidin-4-yl]-1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound C1CC(C(O)(C(F)(F)F)C(F)(F)F)CCN1CC1=CC=C([C@@H]2OC3=CC=CC=C3OC2)C=C1 ISPUBVOAHNAPRV-HXUWFJFHSA-N 0.000 abstract 1
- YLYHYDIKDUVOGJ-MQNHUJCZSA-N 2-[[4-[(3s)-2,3-dihydro-1,4-benzodioxin-3-yl]phenyl]methyl]-3,4-dihydro-1h-isoquinoline-4-carboxylic acid Chemical compound C1C2=CC=CC=C2C(C(=O)O)CN1CC1=CC=C([C@@H]2OC3=CC=CC=C3OC2)C=C1 YLYHYDIKDUVOGJ-MQNHUJCZSA-N 0.000 abstract 1
- ZWUUPDYTGUTSJH-UHFFFAOYSA-N 3-[4-(morpholin-4-ylmethyl)phenyl]-2,3-dihydro-[1,4]dioxino[2,3-b]pyridine Chemical compound C=1C=C(C2OC3=NC=CC=C3OC2)C=CC=1CN1CCOCC1 ZWUUPDYTGUTSJH-UHFFFAOYSA-N 0.000 abstract 1
- UQQLICXYPNBOEZ-UHFFFAOYSA-N 3-[4-(pyrrolidin-1-ylmethyl)phenyl]-2,3-dihydro-[1,4]dioxino[2,3-b]pyridine Chemical compound C=1C=C(C2OC3=NC=CC=C3OC2)C=CC=1CN1CCCC1 UQQLICXYPNBOEZ-UHFFFAOYSA-N 0.000 abstract 1
- DPBWFNDFMCCGGJ-UHFFFAOYSA-N 4-Piperidine carboxamide Chemical compound NC(=O)C1CCNCC1 DPBWFNDFMCCGGJ-UHFFFAOYSA-N 0.000 abstract 1
- FPRBMLMQAPKJFM-UHFFFAOYSA-N 4-[1-[[4-(2,3-dihydro-1,4-benzodioxin-3-yl)phenyl]methyl]piperidin-4-yl]butanoic acid Chemical compound C1CC(CCCC(=O)O)CCN1CC1=CC=C(C2OC3=CC=CC=C3OC2)C=C1 FPRBMLMQAPKJFM-UHFFFAOYSA-N 0.000 abstract 1
- PJISTLZINZMEAV-UHFFFAOYSA-N 4-[[4-(2,3-dihydro-1,4-benzodioxin-3-yl)phenyl]methyl]-1,4-oxazepane Chemical compound C=1C=C(C2OC3=CC=CC=C3OC2)C=CC=1CN1CCCOCC1 PJISTLZINZMEAV-UHFFFAOYSA-N 0.000 abstract 1
- XXPBYOHOUYUZAJ-UHFFFAOYSA-N 4-[[4-(2,3-dihydro-1,4-benzodioxin-3-yl)phenyl]methyl]morpholine Chemical compound C=1C=C(C2OC3=CC=CC=C3OC2)C=CC=1CN1CCOCC1 XXPBYOHOUYUZAJ-UHFFFAOYSA-N 0.000 abstract 1
- IKWWVMGPYFHWIW-UHFFFAOYSA-N 4-[[4-(2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-3-yl)phenyl]methyl]-1,4-thiazinane 1,1-dioxide Chemical compound C1CS(=O)(=O)CCN1CC1=CC=C(C2OC3=NC=CC=C3OC2)C=C1 IKWWVMGPYFHWIW-UHFFFAOYSA-N 0.000 abstract 1
- OJNRYJSREIBHKN-UHFFFAOYSA-N 7-[[4-(2,3-dihydro-1,4-benzodioxin-3-yl)phenyl]methyl]-6,8-dihydro-5h-[1,2,4]triazolo[4,3-a]pyrazine Chemical compound C1OC2=CC=CC=C2OC1C(C=C1)=CC=C1CN1CC2=NN=CN2CC1 OJNRYJSREIBHKN-UHFFFAOYSA-N 0.000 abstract 1
- IIOWUXSXCPNKIJ-UHFFFAOYSA-N 7-[[4-(2,3-dihydro-1,4-benzodioxin-3-yl)phenyl]methyl]-7-azabicyclo[2.2.1]heptane Chemical compound C1OC2=CC=CC=C2OC1C(C=C1)=CC=C1CN1C2CCC1CC2 IIOWUXSXCPNKIJ-UHFFFAOYSA-N 0.000 abstract 1
- JXCIUGPJSUFJOD-UHFFFAOYSA-N 8-[[4-(2,3-dihydro-1,4-benzodioxin-3-yl)phenyl]methyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound N1C(=O)NC(=O)C11CCN(CC=2C=CC(=CC=2)C2OC3=CC=CC=C3OC2)CC1 JXCIUGPJSUFJOD-UHFFFAOYSA-N 0.000 abstract 1
- XVXNHQQZVJIOKW-UHFFFAOYSA-N 8-[[4-(2,3-dihydro-1,4-benzodioxin-3-yl)phenyl]methyl]-2,8-diazaspiro[4.5]decan-1-one Chemical compound O=C1NCCC11CCN(CC=2C=CC(=CC=2)C2OC3=CC=CC=C3OC2)CC1 XVXNHQQZVJIOKW-UHFFFAOYSA-N 0.000 abstract 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 abstract 1
- XPGRTZHBPYGXGA-UHFFFAOYSA-N [1-[[4-(2,3-dihydro-1,4-benzodioxin-3-yl)phenyl]methyl]piperidin-4-yl]methanol Chemical compound C1CC(CO)CCN1CC1=CC=C(C2OC3=CC=CC=C3OC2)C=C1 XPGRTZHBPYGXGA-UHFFFAOYSA-N 0.000 abstract 1
- HUIQHYCNINCSRR-UHFFFAOYSA-N [1-[[4-(2,3-dihydro-1,4-benzodioxin-3-yl)phenyl]methyl]piperidin-4-yl]urea Chemical compound C1CC(NC(=O)N)CCN1CC1=CC=C(C2OC3=CC=CC=C3OC2)C=C1 HUIQHYCNINCSRR-UHFFFAOYSA-N 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- MHPUGCYGQWGLJL-UHFFFAOYSA-N dimethyl pentanoic acid Natural products CC(C)CCCC(O)=O MHPUGCYGQWGLJL-UHFFFAOYSA-N 0.000 abstract 1
- 125000005647 linker group Chemical group 0.000 abstract 1
- DUNJXOQNDVMPPN-UHFFFAOYSA-N n-[[4-(2,3-dihydro-1,4-benzodioxin-3-yl)phenyl]methyl]-2-methoxy-n-methylethanamine Chemical compound C1=CC(CN(C)CCOC)=CC=C1C1OC2=CC=CC=C2OC1 DUNJXOQNDVMPPN-UHFFFAOYSA-N 0.000 abstract 1
- KDLGHKWTKLMJCM-UHFFFAOYSA-N n-[[4-(2,3-dihydro-1,4-benzodioxin-3-yl)phenyl]methyl]-2-methyl-1-pyrrolidin-1-ylpropan-2-amine Chemical compound C=1C=C(C2OC3=CC=CC=C3OC2)C=CC=1CNC(C)(C)CN1CCCC1 KDLGHKWTKLMJCM-UHFFFAOYSA-N 0.000 abstract 1
- RBCJVTJYZOHMJB-UHFFFAOYSA-N n-[[4-(2,3-dihydro-1,4-benzodioxin-3-yl)phenyl]methyl]-2-methylpropan-2-amine Chemical compound C1=CC(CNC(C)(C)C)=CC=C1C1OC2=CC=CC=C2OC1 RBCJVTJYZOHMJB-UHFFFAOYSA-N 0.000 abstract 1
- SDTKSUIXCHXJGA-UHFFFAOYSA-N n-[[4-(2,3-dihydro-1,4-benzodioxin-3-yl)phenyl]methyl]-n-ethylethanamine Chemical compound C1=CC(CN(CC)CC)=CC=C1C1OC2=CC=CC=C2OC1 SDTKSUIXCHXJGA-UHFFFAOYSA-N 0.000 abstract 1
- APBRJZMTCWURBA-UHFFFAOYSA-N n-[[4-(2,3-dihydro-1,4-benzodioxin-3-yl)phenyl]methyl]-n-methyl-2-pyridin-2-ylethanamine Chemical compound C=1C=C(C2OC3=CC=CC=C3OC2)C=CC=1CN(C)CCC1=CC=CC=N1 APBRJZMTCWURBA-UHFFFAOYSA-N 0.000 abstract 1
- UJGZYZOCODVOBX-UHFFFAOYSA-N n-[[4-(2,3-dihydro-1,4-benzodioxin-3-yl)phenyl]methyl]cyclopentanamine Chemical compound C=1C=C(C2OC3=CC=CC=C3OC2)C=CC=1CNC1CCCC1 UJGZYZOCODVOBX-UHFFFAOYSA-N 0.000 abstract 1
- JQIIDQWKMWVKCZ-JOCHJYFZSA-N n-[[4-[(3s)-2,3-dihydro-1,4-benzodioxin-3-yl]phenyl]methyl]-n-methyl-1-methylsulfonylpiperidin-4-amine Chemical compound C=1C=C([C@@H]2OC3=CC=CC=C3OC2)C=CC=1CN(C)C1CCN(S(C)(=O)=O)CC1 JQIIDQWKMWVKCZ-JOCHJYFZSA-N 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Reivindicación 1: Una combinación caracterizada porque comprende un compuesto de la fórmula (1) o una sal de este aceptable desde el punto de vista farmacéutico, en donde: X es N o CH; n es un entero de 0 a 3; R¹ se selecciona de halo, -OH, -CN, -alquilo C₁₋₆, -O-alquilo C₁₋₆ y -cicloalquilo C₃₋₆; R² y R³ se seleccionan, cada uno, independientemente de -H y -alquilo C₁₋₆; en donde R²y R³ pueden unirse para formar un anillo de 3 a 6 miembros que comprende, opcionalmente, de 1 a 3 heteroátomos, opcionalmente también sustituido con 1 a 3 grupos seleccionados de halo, -OH, (=O), -alquilo C₁₋₆, -O-alquilo C₁₋₆, -C(O)OH, -C(O)alquilo C₁₋₆ y -C(O)NH₂; A es un grupo de la fórmula -NR⁴R⁵, en donde R⁴ y R⁵ se seleccionan, cada uno, independientemente de -H, -alquilo C₁₋₆, -cicloalquilo C₃₋₆, -heterocicloalquilo (de 4 a 14 miembros), -arilo C₆₋₁₀ y -heteroarilo (de 5 a 11 miembros); en donde cada uno de los anteriores -alquilo C₁₋₆, -cicloalquilo C₃₋₆, -heterocicloalquilo (de 4 a 14 miembros), -arilo C₆₋₁₀ y heteroarilo -(de 5 a 11 miembros) de dichos grupos R⁴ y R⁵ se sustituye de manera opcional e independiente con 1 a 3 grupos R⁶; en donde dos grupos R⁶, cuando se ligan al mismo átomo de carbono de dicho -alquilo C₁₋₆, pueden unirse para formar un anillo de 3 a 6 miembros que comprende, opcionalmente, de 1 a 3 heteroátomos, opcionalmente también sustituido con 1 a 3 grupos seleccionados de halo, -OH, (=O), -alquilo C₁₋₆, -O-alquilo C₁₋₆, -C(O)OH, -C(O)alquilo C₁₋₆ y -C(O)NH₂; A es un anillo N-heterocíclico (de 4 a 14 miembros) de la fórmula (2) en donde el anillo B es: (c) un radical monocíclico no aromático de 4 - 8 miembros; o (d) un radical bicíclico en puente, un radical spirocíclico o un radical bicíclico fusionado de 6 a 11 miembros, en donde cada radical bicíclico en puente, radical spirocíclico y radical bicíclico fusionado de 6 a 11 miembros comprende al menos un anillo N-heterocíclico no aromático que se une al átomo de carbono 1 del compuesto de la fórmula (1); en donde cada radical bicíclico en puente, radical spirocíclico y radical bicíclico fusionado de 6 a 11 miembros puede comprender opcionalmente un anillo aromático; en donde dicho anillo B también puede comprender de 1 a 3 heteroátomos adicionales del anillo seleccionados independientemente de N, O y S; en donde dicho anillo B también se puede sustituir opcionalmente con 1 a 3 grupos seleccionados de halo, -OH, (=O), -C(O)OH, -C(O)O-alquilo C₁₋₆ y -alquilo C₁₋₆; y en donde L está ausente o es un ligador seleccionado de -alquileno C₁₋₆; cada R⁶ se selecciona independientemente de halo, -OR⁷, -CF₃, -CN, -alquilo C₁₋₆, -O-alquilo C₁₋₆, -C(O)R⁷, -C(O)₂R⁷, -C(O)N(R⁷)₂, -N(R⁷)₂, -NHC(O)R⁷, -NHC(O)N(R⁷)₂, -S(O)₂R⁷, -NH-S(O)₂-R⁷, -cicloalquilo C₃₋₆, heterocicloalquilo (de 4 a 14 miembros), -arilo C₆₋₁₀ y heteroarilo (de 5 a 11 miembros); en donde cada uno de -alquilo C₁₋₆, -O-alquilo C₁₋₆, -cicloalquilo C₃₋₆, heterocicloalquilo (de 4 a 14 miembros), -arilo C₆₋₁₀ y heteroarilo (de 5 a 11 miembros) del grupo R⁶ se sustituye opcionalmente, cuando fuese posible, con 1 a 3 grupos seleccionados de halo, -OH, -CF₃, -CN, (=O), -alquilo C₁₋₆, -C(O)O-H, -C(O)O-alquilo C₁₋₆, -NH₂, -NH-alquilo C₁₋₆, -N(alquilo C₁₋₆)₂, -S(O)₂alquilo C₁₋₆, -cicloalquilo C₃₋₆, heterocicloalquilo (de 4 a 14 miembros), -arilo C₆₋₁₀ y heteroarilo (de 5 a 11 miembros); y cada R⁷ se selecciona independientemente de -H, -alquilo C₁₋₆, -alquil C₁₋₆-OH, -alquil C₁₋₆-O-alquilo C₁₋₆, -O-alquilo C₁₋₆, -cicloalquilo C₃₋₆, -cicloalquil C₃₋₆-OH, heterocicloalquilo (de 4 a 14 miembros), -arilo C₆₋₁₀ y heteroarilo (de 5 a 11 miembros); en donde cada uno de los grupos R⁷ se sustituye opcionalmente, cuando fuese posible, con un grupo seleccionado de -OH, -NH-alquilo C₁₋₆, -NHC(O)alquilo C₁₋₆, -C(O)NH₂, -S(O)₂alquilo C₁₋₆ y heterocicloalquilo (de 4 a 14 miembros); en donde el grupo heterocicloalquilo (de 4 a 14 miembros) se sustituye opcionalmente, cuando fuese posible, con un grupo (=O); y uno o más agentes activos adicionales. Reivindicación 2: La combinación de la reivindicación 1, caracterizada porque el compuesto de la fórmula (1) se selecciona del grupo que consiste en: 1-[4-(2,3-dihidro-1,4-benzodioxin-2-il)bencil]pirrolidina, 4-[4-(2,3-dihidro-1,4-benzodioxin-2-il)bencil]morfolina, 1-[4-(2,3-dihidro-1,4-benzodioxin-2-il)bencil]-4,4-dimetilpiperidina, 8-[4-(2,3-dihidro-1,4-benzodioxin-2-il)bencil]-2,8-diazaspiro[4.5]decan-1-ona, 1-[4-(2,3-dihidro-1,4-benzodioxin-2-il)bencil]-4-fluoropiperidina, (1s,4s)-7-[4-(2,3-dihidro-1,4-benzodioxin-2-il)bencil]-7-azabiciclo[2.2.1]heptano, 1,1-dióxido de 4-[4-(2,3-dihidro-1,4-benzodioxin-2-il)bencil]tiomorfolina, 1-{4-[(2S)-2,3-dihidro-1,4-benzodioxin-2-il]bencil}-N,N-dimetilpiperidin-4-carboxamida, (3S)-1-[4-(2,3-dihidro-1,4-benzodioxin-2-il)bencil]pirrolidin-3-ol, 1-({1-[4-(2,3-dihidro-1,4-benzodioxin-2-il)bencil]piperidin-3-il}metil)pirrolidin-2-ona, 1-{4-[4-(2,3-dihidro-1,4-benzodioxin-2-il)bencil]piperazin-1-il}etanona, 2-{[4-(2,3-dihidro-1,4-benzodioxin-2-il)bencil]amino}-1-(pirrolidin-1-il)etanona, N-{4-[(2S)-2,3-dihidro-1,4-benzodioxin-2-il]bencil}-N-metil-1-(metilsulfonil)piperidin-4-amina, 1-{4-[{4-[(2S)-2,3-dihidro-1,4-benzodioxin-2-il]bencil}(metil)amino]piperidin-1-il}etanona, 3-[4-(pirrolidin-1-ilmetil)fenil]-2,3-dihidro[1,4]dioxino[2,3-b]piridina, 7-[4-(2,3-dihidro-1,4-benzodioxin-2-il)bencil]-5,6,7,8-tetrahidro[1,2,4]triazolo[4,3-a]pirazina, 3-{4-[(1,1-dioxidotiomorfolin-4-il)metil]fenil}-2,3-dihidro[1,4]dioxino[2,3-b]piridina, 3-[4-(morfolin-4-ilmetil)fenil]-2,3-dihidro[1,4]dioxino[2,3-b]piridina, ácido (3R)-1-{4-[(2S)-2,3-dihidro-1,4-benzodioxin-2-il]bencil}piperidin-3-carboxílico, ácido (3S)-1-{4-[(2S)-2,3-dihidro-1,4-benzodioxin-2-il]bencil}piperidin-3-carboxílico, 1-(1-{4-[(2S)-2,3-dihidro-1,4-benzodioxin-2-il]bencil}piperidin-4-il)-2,2,2-trifluoroetanol, 2-(1-{4-[(2S)-2,3-dihidro-1,4-benzodioxin-2-il]bencil}piperidin-4-il)-1,1,1,3,3,3-hexafluoropropan-2-ol, N-[4-(2,3-dihidro-1,4-benzodioxin-2-il)bencil]-2-metilpropan-2-amina, (2R)-N-[4-(2,3-dihidro-1,4-benzodioxin-2-il)bencil]butan-2-amina, 1-[4-(2,3-dihidro-1,4-benzodioxin-2-il)bencil]-N-metilpiperidin-4-carboxamida, ácido 4-{1-[4-(2,3-dihidro-1,4-benzodioxin-2-il)bencil]piperidin-4-il}butanoico, {1-[4-(2,3-dihidro-1,4-benzodioxin-2-il)bencil]piperidin-4-il}metanol, 2-{1-[4-(2,3-dihidro-1,4-benzodioxin-2-il)bencil]piperidin-4-il}propan-2-oI, 3-{1-[4(2,3-dihidro-1,4-benzodioxin-2-il)bencil]piperidin-4-il}propan-1-oI, 1-[4-(2,3-dihidro-1,4-benzodioxin-2-il)bencil]-4-metil-1,4-diazepan, 1-{4-[4-(2,3-dihidro-1,4-benzodioxin-2-il)bencil]-1,4-diazepan-1-il}etanona, 4-[4-(2,3-dihidro-1,4-benzodioxin-2-il)bencil]-1,4-oxazepan, N-[4-(2,3-dihidro-1,4-benzodioxin-2-il)bencil]-2-metoxi-N-metiletanamina, (3R)-1-[4-(2,3-dihidro-1,4-benzodioxin-2-il)bencil]pirrolidin-3-oI, 8-[4-(2,3-dihidro-1,4-benzodioxin-2-il)bencil]-1,3,8-triazaspiro[4.5]decan-2,4-diona, 1-[4-(2,3-dihidro-1,4-benzodioxin-2-il)bencil]-3-metoxiazetidina, {1-[4-(2,3-dihidro-1,4-benzodioxin-2-il)bencil]piperidin-4-il}(morfolin-4-il)metanona 2-{1-[4-(2,3-dihidro-1,4-benzodioxin-2-il)bencil]piperidin-4-il}-N,N-dimetilacetamida, 1-[4-(2,3-dihidro-1,4-benzodioxin-2-il)bencil]-4-(metilsulfonil)piperidina, 1-[4-(2,3-dihidro-1,4-benzodioxin-2-il)bencil]azepan, N-[4-(2,3-dihidro-1,4-benzodioxin-2-il)bencil]ciclopentanamina, N-[4-(2,3-dihidro-1,4-benzodioxin-2-il)bencil]-N-metil-2(piridin-2-il)etanamina, 1-ciclopropil-N-[4-(2,3-dihidro-1,4-benzodioxin-2-il)bencil]metanamina, 1-[4-(2,3-dihidro-1,4-benzodioxin-2-il)bencil]-4-fenilpiperidin-4-ol, N-[4-(2,3-dihidro-1,4-benzodioxin-2-il)bencil]-N-etiletanamina, 1-[4-(2,3-dihidro-1,4-benzodioxin-2-il)bencil]azetidin-3-carbonitrilo, 1-[4-(2,3-dihidro-1,4-benzodioxin-2-il)bencil]-3-metoxipirrolidina N-{1-[4-(2,3-dihidro-1,4-benzodioxin-2-il)bencil]piperidin-4-il}metansulfonamida, N-[4-(2,3-dihidro-1,4-benzodioxin-2-il)bencil]-2-metil-1-(pirrolidin-1-il)propan-2-amina, 1-({1-[4-(2,3-dihidro-1,4-benzodioxin-2-il)bencil]piperidin-4-il}metil)pirrolidin-2-ona, 1-[4-(2,3-dihidro-1,4-benzodioxin-2-il)bencil]-N,N-dimetilpiperidin-4-carboxamida, 1-[4-(2,3-dihidro-1,4-benzodioxin-2-il)bencil]-N-(2-hidroxietiI)piperidin-4-carboxamida, 1-{1-[4-(2,3-dihidro-1,4-benzodioxin-2-il)bencil]piperidin-4-il}urea, 1-[4-(2,3-dihidro-1,4-benzodioxin-2-il)fenil]-N-(piridin-3-ilmetil)metanamina, 1-[4-(2,3-dihidro-1,4-benzodioxin-2-il)fenil]-N-[(1-metil-1H-imidazol-4-il)metil]metanamina, ácido 2-{4-[(2S)-2,3-dihidro-1,4-benzodioxin-2-il]bencil}-1,2,3,4-tetrahidroisoquinolin-4-carboxílico, ácido (1R,3S)-3-({4-[(2S)-2,3-dihidro-1,4-benzodioxin-2-il]bencil}amino)ciclopentancarboxilico, ácido 3-({4-[(2S)-2,3-dihidro-1,4-benzodioxin-2-il]bencil}amino)-4,4,dimetilpentanoico, ácido 1-({4-[(2S)-2,3-dihidro
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261607149P | 2012-03-06 | 2012-03-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR090259A1 true AR090259A1 (es) | 2014-10-29 |
Family
ID=47833062
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130100729A AR090259A1 (es) | 2012-03-06 | 2013-03-05 | Inhibidores de benzodioxano de la produccion de leucotrieno para terapia de combinacion |
Country Status (16)
Country | Link |
---|---|
US (1) | US9662339B2 (es) |
EP (1) | EP2822941B1 (es) |
JP (1) | JP6080226B2 (es) |
KR (1) | KR20140138851A (es) |
CN (1) | CN104487435A (es) |
AR (1) | AR090259A1 (es) |
AU (1) | AU2013229560A1 (es) |
CA (1) | CA2866471A1 (es) |
CL (1) | CL2014002326A1 (es) |
EA (1) | EA201400976A1 (es) |
MX (1) | MX2014010563A (es) |
NZ (1) | NZ628587A (es) |
PH (1) | PH12014501967A1 (es) |
TW (1) | TW201350475A (es) |
UY (1) | UY34661A (es) |
WO (1) | WO2013131901A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2835617C (en) | 2011-03-14 | 2020-07-21 | Boehringer Ingelheim International Gmbh | Benzodioxane inhibitors of leukotriene production |
US9139567B2 (en) | 2011-07-19 | 2015-09-22 | Boehringer Ingelheim International Gmbh | Arylpyrazole ethers as inhibitors of leukotriene A4 hydrolase |
AR091315A1 (es) | 2012-03-06 | 2015-01-28 | Boehringer Ingelheim Int | Inhibidores de benzodioxano de la produccion de leucotrieno |
JP6080226B2 (ja) | 2012-03-06 | 2017-02-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 他の活性物質と組み合わせたロイコトリエン産生阻害用ベンゾジオキサン |
US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
EP2885285B1 (en) | 2012-07-17 | 2016-10-19 | Boehringer Ingelheim International GmbH | Pyrazole drivatives which inhibit leukotriene production |
PL2978859T3 (pl) | 2013-03-27 | 2018-10-31 | F.Hoffmann-La Roche Ag | Markery genetyczne do przewidywania reakcji na terapię |
JP6353899B2 (ja) | 2013-07-15 | 2018-07-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ロイコトリエン生成の阻害剤 |
JP2016523982A (ja) | 2013-07-15 | 2016-08-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ロイコトリエン生成の阻害剤 |
EP3174995B1 (en) | 2014-07-30 | 2020-08-19 | F.Hoffmann-La Roche Ag | Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent |
EP3177287B1 (en) * | 2014-08-08 | 2022-02-23 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
CN104181252B (zh) * | 2014-09-01 | 2015-12-02 | 广东东阳光药业有限公司 | 一种分离检测安塞曲匹及其异构体的方法 |
CN105748469B (zh) * | 2016-02-24 | 2019-07-23 | 长沙佰顺生物科技有限公司 | 一种安塞曲匹辛伐他汀药物组合物 |
WO2017170830A1 (ja) * | 2016-03-31 | 2017-10-05 | 武田薬品工業株式会社 | 複素環化合物 |
KR20230051227A (ko) | 2020-08-14 | 2023-04-17 | 노파르티스 아게 | 헤테로아릴 치환된 스피로피페리디닐 유도체 및 이의 제약 용도 |
CN112076189B (zh) * | 2020-09-23 | 2021-11-12 | 唐怡庭 | 一种酰胺化合物在制备治疗脓毒症药物中的应用 |
CA3221177A1 (en) | 2021-11-01 | 2023-05-04 | Meghan Kerrisk Campbell | Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US498770A (en) * | 1893-06-06 | Electrolytic apparatus | ||
US4918092A (en) * | 1983-12-21 | 1990-04-17 | Merck Frosst Canada, Inc. | Leukotriene antagonists |
US5120758A (en) | 1991-02-08 | 1992-06-09 | Ciba-Geigy Corporation | Certain benzodioxole, benzodioxane and benzodioxepin derivatives useful as 5-lipoxygenase inhibitors |
DE4127849A1 (de) | 1991-08-22 | 1993-02-25 | Merck Patent Gmbh | Benzodioxanderivate |
US5585492A (en) * | 1994-10-11 | 1996-12-17 | G. D. Searle & Co. | LTA4 Hydrolase inhibitors |
US6506876B1 (en) | 1994-10-11 | 2003-01-14 | G.D. Searle & Co. | LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use |
DE19705450A1 (de) | 1997-02-13 | 1998-08-20 | Merck Patent Gmbh | Bicyclische aromatische Aminosäuren |
DE19821003A1 (de) | 1998-05-11 | 1999-11-18 | Dresden Arzneimittel | Neue 1,2,5-trisubstituierte 1,2-dihydro-indazol-3-one mit antiasthmatischer, antiallergischer, entzündungshemmender, immunmodulierender und neuroprotektiver Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
JP2004512327A (ja) | 2000-10-26 | 2004-04-22 | ファイザー・プロダクツ・インク | ピリミジン−2,4,6−トリオン・メタロプロテイナーゼ阻害剤 |
US20060019269A1 (en) * | 2002-10-17 | 2006-01-26 | Decode Genetics, Inc. | Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment |
DK1572215T3 (da) | 2002-12-20 | 2010-01-11 | Glaxo Group Ltd | Benzo[D]azepin-derivater til behandling af neurologiske lidelser |
US7098222B2 (en) | 2004-05-12 | 2006-08-29 | Abbott Laboratories | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
AP2362A (en) | 2005-01-07 | 2012-02-08 | Pfizer Prod Inc | Heteroaromatic quinoline compounds and their use as PDE10 inhibitors. |
JP2008536825A (ja) | 2005-03-31 | 2008-09-11 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | フェニルおよびピリジルlta4hモジュレータ |
NZ566788A (en) | 2005-09-21 | 2012-10-26 | Decode Genetics Ehf | Biaryl substituted heterocycle inhibitors of LTA4H for treating inflammation |
US7674802B2 (en) | 2005-12-21 | 2010-03-09 | Decode Genetics, Ehf | N-linked aryl heteroaryl inhibitors of LTA4H for treating inflammation |
AU2006333522A1 (en) | 2005-12-21 | 2007-07-12 | Decode Genetics, Ehf. | Biaryl nitrogen heterocycle inhibitors of LTA4H for treating inflammation |
WO2008052086A1 (en) | 2006-10-24 | 2008-05-02 | Wyeth | Benzodioxane derivatives and uses thereof |
PT2336125E (pt) | 2008-04-11 | 2013-03-18 | Janssen Pharmaceutica Nv | Tiazolopiridina-2-iloxi-fenil e tiazolopirazin-2-iloxifenil aminas como moduladores de leucotrieno a4 hidrolase |
BRPI1014039A2 (pt) | 2009-04-08 | 2018-04-03 | Actelion Pharmaceuticals Ltd | 6-(3-aza-biciclo[3.1.0]hex-3-il)-2-fenil-pirimidinas |
WO2011032050A2 (en) | 2009-09-11 | 2011-03-17 | Trius Therapeutics, Inc. | Gyrase inhibitors |
WO2011114220A1 (en) | 2010-03-18 | 2011-09-22 | Biotechnology Research Corporation Limited | Neuro-protective effects of adelostemma gracillimum and its isolated compounds |
CA2835617C (en) * | 2011-03-14 | 2020-07-21 | Boehringer Ingelheim International Gmbh | Benzodioxane inhibitors of leukotriene production |
US9139567B2 (en) | 2011-07-19 | 2015-09-22 | Boehringer Ingelheim International Gmbh | Arylpyrazole ethers as inhibitors of leukotriene A4 hydrolase |
JP6080226B2 (ja) | 2012-03-06 | 2017-02-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 他の活性物質と組み合わせたロイコトリエン産生阻害用ベンゾジオキサン |
AR091315A1 (es) | 2012-03-06 | 2015-01-28 | Boehringer Ingelheim Int | Inhibidores de benzodioxano de la produccion de leucotrieno |
EP2885285B1 (en) | 2012-07-17 | 2016-10-19 | Boehringer Ingelheim International GmbH | Pyrazole drivatives which inhibit leukotriene production |
-
2013
- 2013-03-05 JP JP2014560334A patent/JP6080226B2/ja active Active
- 2013-03-05 CA CA2866471A patent/CA2866471A1/en not_active Abandoned
- 2013-03-05 US US13/785,097 patent/US9662339B2/en active Active
- 2013-03-05 AU AU2013229560A patent/AU2013229560A1/en not_active Abandoned
- 2013-03-05 AR ARP130100729A patent/AR090259A1/es unknown
- 2013-03-05 TW TW102107706A patent/TW201350475A/zh unknown
- 2013-03-05 WO PCT/EP2013/054381 patent/WO2013131901A1/en active Application Filing
- 2013-03-05 KR KR1020147027959A patent/KR20140138851A/ko not_active Application Discontinuation
- 2013-03-05 MX MX2014010563A patent/MX2014010563A/es unknown
- 2013-03-05 EA EA201400976A patent/EA201400976A1/ru unknown
- 2013-03-05 NZ NZ628587A patent/NZ628587A/en not_active IP Right Cessation
- 2013-03-05 EP EP13707858.0A patent/EP2822941B1/en active Active
- 2013-03-05 CN CN201380022189.8A patent/CN104487435A/zh active Pending
- 2013-03-06 UY UY0001034661A patent/UY34661A/es unknown
-
2014
- 2014-09-01 CL CL2014002326A patent/CL2014002326A1/es unknown
- 2014-09-03 PH PH12014501967A patent/PH12014501967A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
PH12014501967B1 (en) | 2014-11-17 |
PH12014501967A1 (en) | 2014-11-17 |
KR20140138851A (ko) | 2014-12-04 |
CL2014002326A1 (es) | 2014-11-14 |
UY34661A (es) | 2013-09-30 |
AU2013229560A1 (en) | 2014-08-28 |
JP6080226B2 (ja) | 2017-02-15 |
WO2013131901A1 (en) | 2013-09-12 |
US9662339B2 (en) | 2017-05-30 |
US20130236468A1 (en) | 2013-09-12 |
CN104487435A (zh) | 2015-04-01 |
MX2014010563A (es) | 2014-12-05 |
EP2822941A1 (en) | 2015-01-14 |
EA201400976A1 (ru) | 2015-02-27 |
EP2822941B1 (en) | 2017-05-10 |
CA2866471A1 (en) | 2013-09-12 |
TW201350475A (zh) | 2013-12-16 |
JP2015513552A (ja) | 2015-05-14 |
NZ628587A (en) | 2016-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR090259A1 (es) | Inhibidores de benzodioxano de la produccion de leucotrieno para terapia de combinacion | |
JP2015513552A5 (es) | ||
AR078168A1 (es) | Derivados de piperidinas y piperazinas, procesos para prepararlos y sus usos como moduladores de gpr119 | |
JP5265913B2 (ja) | アミド化合物およびその医薬としての使用 | |
EA039493B1 (ru) | Биарилметильные гетероциклы | |
RU2012143689A (ru) | Спироциклические соединения и их применение в качестве терапевтических агентов и диагностических зондов | |
WO2022078407A1 (en) | Heterocyclic glp-1 agonists | |
US9949979B2 (en) | Use of inhibitors of the activity or function of PI3K | |
HRP20161774T1 (hr) | Novi diazaspirocikloalkan i azaspirocikloalkan | |
US8623859B2 (en) | Bradykinin B1 antagonists | |
US8946203B2 (en) | Benzodioxane inhibitors of leukotriene production | |
WO2014014874A1 (en) | Pyrazole derivatives which inhibit leukotriene production | |
EA013249B1 (ru) | Производные тиазола | |
RU2008126391A (ru) | Производные 1,5-замещенного индол-2-иламида | |
JP2013522286A5 (es) | ||
EP2766352A1 (en) | Indazole compounds as kinase inhibitors and method of treating cancer with same | |
RU2012104244A (ru) | Аналоги tofa, применимые при лечении дерматологических расстройств или состояний | |
CA2962578A1 (en) | Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds | |
RU2010118018A (ru) | Хиральные цис-имидазолины | |
AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
EA012607B1 (ru) | НОВЫЕ ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ NF-κB | |
CN102123990A (zh) | 杂环化合物及其用途 | |
RU2015143676A (ru) | Модулятолры ship1 и относящиеся к ним способы | |
KR20180014832A (ko) | Nadph 옥시다제 4 억제제 | |
RU2013157374A (ru) | Производное индазола и пирролопиридина и его фармацевтическое применение |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |